Atazanavir/ritonavir
Combination of
AtazanavirProtease inhibitor
RitonavirProtease inhibitor (pharmacokinetic booster)
Clinical data
Trade namesRitovaz
Other namesAnzavir-R, ritonavir/atazanavir[1]
Routes of
administration		By mouth[1]
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)

Atazanavir/ritonavir (ATV/r) is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS.[1] It combines atazanavir and ritonavir.[1] It may be used instead of lopinavir/ritonavir.[2] It is taken by mouth.[1]

Side effects are generally minimal.[2] They may include abdominal pain, diarrhea, yellowish skin, muscle pains, and headache.[2] Greater care should be taken in people with underlying liver problems.[2] Use in pregnancy appears to be safe.[3] In the combination atazanavir functions as a protease inhibitor and ritonavir functions to increase levels of atazanavir.[2]

The combination was approved for use in India in 2012, and is pending approval in the United States As of 2017.[1] It is on the World Health Organization's List of Essential Medicines.[4]

References

  1. 1 2 3 4 5 6 "Atazanavir/ritonavir - Mylan Laboratories - AdisInsight". adisinsight.springer.com. Retrieved 29 June 2017.
  2. 1 2 3 4 5 "Atazanavir + ritonavir (Addition) -- Adults". World Health Organization (WHO). Archived from the original on 3 February 2020. Retrieved 29 June 2017.
  3. ↑ "Atazanavir/Ritonavir in Pregnancy". hivinsite.ucsf.edu. Archived from the original on 29 January 2018. Retrieved 10 December 2017.
  4. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.